Text Size

Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Canadian Breast Cancer Foundation
Information provided by:
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT00260975
First received: November 30, 2005
Last updated: August 23, 2010
Last verified: August 2010
History of Changes
  Purpose

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as "chemo fog". The current study is investigating this phenomenon by measuring patients' mental function prior to and after exposure to chemotherapy, and by comparing mental function in those patients who receive chemotherapy and those who do not.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Ottawa Hospital Research Institute:

Estimated Enrollment: 150
Study Start Date: June 2001
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as "chemo fog". The current study will investigate this phenomenon by measuring neuropsychological functioning in early stage breast cancer patients prior to and after exposure to chemotherapy, and by comparing change in cognitive function in these patients who receive chemotherapy to similar breast cancer patients receiving hormonal therapy only, and to healthy women without breast cancer.

  Eligibility

Ages Eligible for Study:   50 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Breast Cancer

Criteria

Inclusion Criteria:

  • stage I or II breast cancer; woman; 50-65 years old; post-menopausal

Exclusion Criteria:

  • history of previous cancer or chemotherapy; significant neurological or psychiatric history
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00260975

Sponsors and Collaborators
Ottawa Hospital Research Institute
Canadian Breast Cancer Foundation
Investigators
Principal Investigator: Barbara Collins OHRI
  More Information

No publications provided

Responsible Party: Dr. Barbara Collins, Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT00260975     History of Changes
Other Study ID Numbers: 1999232-01H
Study First Received: November 30, 2005
Last Updated: August 23, 2010
Health Authority: Canada: Ethics Review Committee

Keywords provided by Ottawa Hospital Research Institute:
breast cancer
chemotherapy
hormonal therapy
cognitive function
chemo fog

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 19, 2013